Recro Pharma, Inc. (NASDAQ:REPH) Files An 8-K Other Events

ME Staff 8-k
-
0

Recro Pharma, Inc. (NASDAQ:REPH) Files An 8-K Other Events
Item 8.01

On November 13, 2019, the Company updated information reflected in a slide presentation, including certain financial information, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

On November 13, 2019, the Company issued a press release announcing the effectiveness of the Baudax Bio, Inc. registration statement on Form 10 in connection with the spin-out of the Company’s acute care segment. A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

(d) Exhibits

The following exhibits are being filed herewith:

99.2    Press release of Recro Pharma, Inc., dated November 13, 2019


Recro Pharma, Inc. Exhibit
EX-99.1 2 d829687dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 …focused on improving patients lives… November 2019Exhibit 99.1 …focused on improving patients lives… November 2019 Forward Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements,…
To view the full exhibit click here

About Recro Pharma, Inc. (NASDAQ:REPH)

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.